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.2012.05.0Abstract The present investigation deals with the development of controlled release tablets of lam-
ivudine using acetylated sago starch. The acetylated starch was synthesized with acetic anhydride in
pyridine medium. The acetylated sago starch was tested for acute toxicity and drug–excipient com-
patibility study. The formulations were evaluated for physical characteristics like hardness, % fri-
ability, % drug content and weight variations. The in vitro release study showed that the optimized
formulation exhibited highest correlation (R) value in the case of higuchi kinetic model and the
release mechanism study proved that the formulation showed a combination of diffusion and ero-
sion processes. There was a signiﬁcant difference in the pharmacokinetic parameters (Tmax, Cmax,
AUC, Vd, T1/2 and MDT) of the optimized formulation as compared to the marketed conventional
tablet Lamivir which proves the controlled release property of acetylated sago starch.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
In recent years, a new generation of biomaterials has been
introduced as modiﬁed polymers for the purpose of controlled
drug release. Different modiﬁcation techniques, such as chem-
ical reaction, complexation reaction and grafting have been ap-
plied to alter native biomaterials by the process of substitution
of functional groups with other compounds (Das and Das,
2003). The use of biodegradable polymers as carriers for con-
trolled release systems has been the object of research over the8439265825; fax: +91 373
l.com (A.V. Singh).
Saud University.
g by Elsevier
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05past few decades due to their advantages over other carrier
systems. Reservoir and matrix type tablets are the most com-
monly used orally administrated sustained release prepara-
tions. Especially matrix tablets, which are produced by direct
compression using either hydrophilic polymer such as natural
gums, HPMC, CMC, Carbopol or hydrophobic, like ethyl cel-
lulose and amylodextrin, which are relatively easy to manufac-
ture (Narasimhan, 2001). Acetylation of starch is an important
modiﬁcation that has been applied to the native starches to im-
part thickening and is known for more than a century. In the
acetylation, parts of the hydroxyl groups of the a-D-glucopyr-
anose units have been converted by esteriﬁcation to acetyl
groups. High acetyl substituted starch with a degree of substi-
tution (DS) of 2–3 was of research interest because of their sol-
ubility in acetone and chloroform and for their thermo
plasticity (Roper, 1996; Jarowenko, 1986). Lamivudine
(LAM) is the ﬁrst nucleoside analogue approved to treat
chronic HBV infection and AIDS. Conventional oral formula-
tions of LAM are administered two times a day 150 mg eachier B.V. All rights reserved.
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ment of AIDS using conventional formulations of LAM is
found to have many drawbacks, such as adverse side effects
resulting from accumulation of drug in multi-dose therapy,
poor patient compliance, and high cost (Perry and Faulds,
1997). Earlier, we have successfully synthesized controlled re-
lease formulation using acetylated moth bean starch in our
laboratory (Singh and Nath, 2012a). The aim of the present
study was to evaluate the chemically modiﬁed (acetylated)
sago starch as hydrophobic inert matrix former in the formu-
lation of controlled release tablets of LAM by direct compres-
sion technique. The formulated tablets were evaluated for
various physical characteristics, in vitro dissolution study and
in vivo pharmacokinetic study in rabbit model.2. Materials and methods
Lamivudine (LAM) was kindly gifted by Ranbaxy Limited,
Paonta Sahib, Himachal Pradesh, India. Spray dried lactose
(SDL) was kindly donated by DMV Fonterra excipients, The
Netherland. Poly vinyl pyrrolidine K-30 (PVP K-30), magne-
sium stearate and talc were purchased from Loba Chemie Lim-
ited, Mumbai, India. All other chemicals used were of
analytical grade and purchased from SD Fine chemical lim-
ited, Mumbai, India.
Digital weighing balance (Sartorius, Germany), Rotary 10
station tablet punching machine (Shakti Engineering Limited,
Ahmedabad, India). UV–Visible Spectrophotometer (UV-
1700, Shimadzu, Japan), HPLC (Waters, USA), Eight basket
digital in vitroUSP dissolution apparatus (Electrolab,Mumbai,
India), Monsano hardness tester and Roche friabilator (Camp-
bell electronics, Mumbai, India), Laboratory scale stability
chamber (Model TH-90 S/G, Thermolab, Mumbai, India).
2.1. Synthesis of acetylated sago starch
Native sago starch was ﬁrst crushed and passed through a sieve
# 120 (0.125 mm). The uniform native sago starch was pregel-
atinized by heating it with water at 70 C. The pregelatinized
starch was dried and sieved through mesh # 60 (0.251 mm).
The acetylation of 25 g pregelatinized starch was done with
100 g acetic anhydride in a medium of 200 g pyridine (Singh
et al., 2011a,b). The reaction was carried out at varying tem-
peratures of 50–150 C and time 1–6 h. The ﬁnal product
was precipitated with ethanol, ﬁltered and dried in vacuum
oven and passed through a sieve # 60 and stored in desiccators
until further study.2.2. Determination of degree of substitution (DS)
Degree of substitution was determined using the method de-
scribed elsewhere (Ogawa et al., 1990). Accurately weighted
1 g of grounded sample was added to the aqueous solution
of ethanol (75% v/v). The slurry was kept in the water bath
for 30 min after the slurry was cooled down, an exact amount
of aqueous solution of potassium hydroxide (0.5 M, 30 mL)was added and the solution was stirred for 72 h. Indicator
(phenolphthalein) was added in excess to the alkali and was
ﬁnally titrated with 0.5 M hydrochloride acid.
Acetyl content (%A) was calculated according to the fol-
lowing Equation:
%Acetyl group ¼ ðValue for blank-value for sampleÞðmLÞðSampling weightÞðgÞ
molarity of HCl 0:043 100
ð2Þ
Acetyl content was used to calculate the degree of substitution,
(DS), according to following Equation:
DS ¼ 162  %acetyl group
4300 ð42  %acetyl groupÞ ð3Þ
where 162 is the molecular weight of the anhydroglucose unit,
42 is the molecular weight of replaceable acetyl group and 4300
is the molecular weight of the acetyl group attached with 100
anhydroglucose unit.
2.3. Acute toxicity study of grafted copolymer
Healthy male and female Swiss albino mice (8 weeks) were
used for the acute oral toxicity study. They were breed and
reared at the animal house of the institution. The animals were
housed in polypropylene cages and provided with bedding of
clean paddy husk. The animals were acclimatized to laboratory
conditions for one week prior to the experiment. The temper-
ature in the animal house was maintained at 25 ± 2 C with a
relative humidity of 30–70% and illumination cycle set to 12 h
light and 12 h dark. The mice were fed with standard labora-
tory pelleted feed (M/s Gold Mohur Foods and Feeds Ltd.,
Bangalore, India). All the mice of both the sexes were fasted
overnight before experimentation and were allowed to take
food one hour after the experiment. Modiﬁed starch was
administered orally at a dose of 2000 mg/kg body weight in
distilled water. The animals were observed for any mortality
and morbidity (convulsions, tremors, and grip strength and
pupil dilatation) at an interval of 12 h for 14 days. This study
was approved by the Animal Ethics Committee of Gayatri
College of pharmacy (Regn. No.1339/ac/10/cpcsea).
2.4. Preformulation study
2.4.1. Drug–excipient compatibility study by DSC
A differential scanning calorimetry (JADE DSC, Perkin
Elmer, USA) was used to study the thermal analysis of
drug–excipient compatibility. Firstly, binary mixtures of lami-
vudine and excipients (in 1:1 mass/mass ratio) were prepared
by using physical mixture technique. The drug–excipient mix-
ture was scanned in the temperature range of 50–220 C under an
atmosphere of nitrogen. The heating rate was 20 C/min and the
obtained thermograms were observed for any type of interaction.
2.4.2. Drug–excipient compatibility study by FT-IR
spectroscopy
FT-IR spectra were recorded on a Bruker spectrophotometer
(Model-220, Germany) using KBr discs in the range of 4000–
450 cm1. FT-IR analysis has been performed using sample
of lamivudine with various excipients and chemically modiﬁed
starches at 1:1 mass/mass ratio.
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In isothermal stress testing (Singh and Nath, 2012b,c) samples
of drug and different excipients were weighed directly in 5 mL
glass vials (n= 3). After mixing on a cyclomixer for 3 min,
10% (w/w) water was added in each of the vials. The glass
vials, after Teﬂon sealing, were stored at 50 C in a hot air
oven. Drug- excipient blends without adding water are stored
in refrigerator that served as controls. The drug–excipient
blends were periodically examined for any change in physical
appearance. Samples were quantitatively analyzed using UV–
Vis spectrophotometer (Pharmaspec 1700, Shimadzu, Japan)
after 4 weeks of storage at the above conditions.
2.5. Formulation of tablets
The lamivudine controlled release tablets were formulated with
common tablet excipients and the model drug as the batch for-
mula is shown in Table 1. The drug, acetylated sago starch
(ASS), spray dried lactose and PVP K-30 were dispensed accu-
rately. Each ingredient was shifted through # 80 sieves, trans-
ferred into a polyethylene bag and mixed for 20 min. The
lubricated dry powder compressed to tablets at 8 kg/cm2 pres-
sure by using 10 mm standard ﬂat punch set in a 10 station ro-
tary tablet punching machine. The tablets were double
wrapped in a polyethylene bag until further study.
2.6. Evaluation of tablets
The tablets from each batch were picked randomly in order to
evaluate the weight variation, the hardness, % drug content
and the friability (Banker and Andsi, 1987). The hardness
and friability of the tablet were measured using Monsanto
hardness tester and Roche friabilator respectively.
2.7. In vitro dissolution rate study
In vitro dissolution rate study of all the formulations (n= 6)
was carried out in USP Type-II dissolution rate test apparatus.
Dissolution rate study was performed in simulated gastric ﬂuid
(0.1 M HCl) and in simulated intestinal ﬂuid (PBS pH 6.8) for
the ﬁrst 2 h and for successive 10 h respectively. The dissolution
medium (900 mL) was maintained at 37 ± 0.5 C throughout
the study. The samples (5 mL) were withdrawn at predeter-
mined times (1, 2, 3, 4, 6, 10, and 12 h) and replaced with an
equivalent volume of fresh medium. The samples were ﬁltered
through membrane ﬁlter (0.45 lm) and analyzed by UV–visible
spectrophotometer at 270 nm (kmax). The cumulative percentTable 1 Composition of lamivudine controlled release tablets using
Ingredients (mg) Formulation code
F1 F2 F3
Lamivudine 100 100 100
Acetylated sago starch 25 50 75
PVP K-30 20 20 20
Spray dried lactose q.s. q.s. q.s.
Magnesium stearate 4 4 4
Talc 4 4 4
Total weight 400 400 400drug release was plotted against time and determined the re-
lease proﬁle.
2.8. Kinetics of drug release
The kinetics of drug release (Costa and Loba, 2001; Hadjiioan-
nou et al., 1993; Higuchi, 1963; Korsemeyer et al., 1985) is
important because it is a useful tool to correlate the in vitro
drug release and in vivo drug responses or to compare the re-
sults of pharmacokinetics with dissolution proﬁles of the for-
mulations. Different mathematical models i.e. zero order,
ﬁrst order, higuchi and Korsemeyer–Peppas equations were
applied for describing the kinetics of the drug release process
from controlled released tablets of LAM, the most suited being
the one which ﬁtted best in the experimental results.
2.9. Pharmacokinetic study
The pharmacokinetic study of optimized controlled release
tablet (F 7) of lamivudine was carried out in two groups of
six male white albino rabbits each weighing 1.5–2.5 kg. All ani-
mals were fasted overnight (12 h) before dosing and continued
till 4.0 h after administration of tablets, thereafter rabbit chew
diet was provided ad libitum. Drinking water was deprived be-
fore dosing and continued till two hours of post dose, thereaf-
ter it was provided ad libitum. The tablets (n= 3) of batch, F
7 was administered orally to three rabbits of each group along
with 10 mL of water by using a feeding tube.
The blood samples (each of about 50 lL from each animal)
were collected from orbital sinus into the microcentrifuge
tubes containing 50 lL of 10% w/w of disodium EDTA as
anticoagulant according to the sampling schedule (pre-
dose,0.25,0.5,1.0,2.0,3.0, 4.0,6.0,9.0,12.0 and 24.0 h). The col-
lected blood samples were centrifuged immediately at 1000·g
for 10 min. The supernatant plasma layer was separated and
stored at 20 C till analysis.
2.10. Plasma sample analysis
Then 200 lL of each sample was taken into a 2 mL centrifuge
tube and 50 lL of nelﬁnavir solution (50 lg/mL) was added as
an internal standard (IS) .The mixtures were vortexed for 10 s.
Acetonitrile (1.5 mL) was added into the mixture, vortexed for
3 min and centrifuged at 10,000 rpm for 10 min. The superna-
tant was transferred into a glass centrifuge tube and evapo-
rated to dryness at 45 C under a stream of nitrogen. The
residue was reconstituted with 200 lL of reconstitution solventASS.
F4 F5 F6 F7 F8
100 100 100 100 100
100 125 150 175 200
20 20 20 20 20
q.s. q.s. q.s. q.s. q.s.
4 4 4 4 4
4 4 4 4 4
400 400 400 400 400
Table 2 Corresponding peak temperatures and enthalpy
values of lamivudine in various drug–excipient mixtures in
DSC study.
Sample Ratio
(drug–excipient)
Tonset
(C)
Tpeak
(C)
DH (J g1
LAM – 177.40 182.73 74.54
LAM+ASS (1:1) 177.68 184.01 98.84
LAM+ PVP K-30 (1:1) 174.32 180.09 72.43
LAM+ SDL (1:1) 171.56 179.44 48.78
LAM+Mag. Stearate (1:1) 177.63 182.91 80.66
LAM+ Talc (1:1) 178.64 183.32 98.38
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membrane ﬁlter using syringe ﬁlter. An aliquot of 20 lL of
the sample was injected into the injector of the HPLC system.
The samples were analyzed by using the chromatographic con-
dition developed in the laboratory (Singh et al., 2011c). The
area under the curve of peaks of LAM and IS was determined
and the concentration of drug present in the sample was
estimated by using the linear regression equation of standard
calibration curve (concentration of LAM vs ratio of LAM to
IS). The amount of drug present in 200 lL of plasma [(quan-
tity obtained from regression equation/200) · 1000)] was
calculated.
2.11. Determination of pharmacokinetic parameters
The pharmacokinetic parameters were determined from the
data of plasma drug concentration at different time points
by using MS-Excel 2003 software according to the procedure
described elsewhere (Jambhekar and Breen, 2009; Bourne,
2001).
2.12. Stability study
Stability study is used to assess expiration dating and storage
conditions for pharmaceutical products. Stability study of lam-
ivudine controlled release tablets were performed as per ICH
guideline. The optimized controlled release tablets were kept
in a polypropylene bottle and stored in a stability chambers
maintained at 40 ± 2 C and 75%± 5% RH for six months.
Samples were checked initially, after three months and further
after six months.Table 3 Results of UV analysis of the drug–excipient mixtures, un
Sample Ratio (drug–excipient) % Drug re
Controlb sa
LAM – 101.12 ± 3
LAM+ASS 1:2 100.34 ± 2
LAM+ SDL 1:2 102.51 ± 2
LAM+ PVP 1:1 103.67 ± 2
LAM+Mag. Stearate 1:1 101.45 ± 1
LAM+ Talc 1:1 101.22 ± 4
a Values expressed as average ± standard deviation (n= 3).
b Drug–excipient blends without added water and stored in refrigerato
c Drug–excipient blends with 10% added water and stored at 50 C fo3. Results and discussion
3.1. Synthesis of highly substituted acetylated sago starch
Starch acetate with high degree of substitution (DS = 2.43)
was synthesized using pyridine as organic solvent. The opti-
mized temperature for synthesizing highly substituted starch
was found to be 100 C. The reaction duration for synthesizing
highest substitution was found to be 4 h, increasing the dura-
tion also caused starch granule destruction which restricts acet-
ylation of sago starch. The degree of substitution of the
acetylated sago starch was measured 2.43 by titrimetric
analysis.
3.2. Acute toxicity study
The purpose of this study was to evaluate toxicity proﬁle of the
modiﬁed starch. A 14 day acute oral toxicity study was per-
formed in swiss albino mice. The LD50 of all the modiﬁed
starches were not further studied as they were found to be safe
up to 2000 mg/kg on 24 h study basis. It was observed that the
animals fed with the modiﬁed starches were found to be
healthy. No unusual changes in behavior, or in locomotor
activity, ataxia, and signs of toxicity were observed during
the 14 days period. No differences were found in growth
behavior between the control and treatment group in 14 days
of study. The body weight of male and female swiss albino
mice was found to be normal after treatment. There was no
change observed in body weight of control and modiﬁed starch
treated mice.
3.3. Preformulation study
3.3.1. Drug- excipient compatibility study by DSC
DSC thermograms of drug and drug–excipient mixtures with
their corresponding peak temperatures and enthalpy values
(DH) of Lamivudine (LAM) with various excipient mixtures
are summarized in Table 2. DSC thermogram of LAM showed
a sharp endothermic peak at 182.73 C corresponding to its
melting point. The endothermic peak of the drug was well re-
tained in the majority of cases. However, in some combina-
tions there were slight changes in peak temperature and peak
shape, which might be due to reduction of the purity level of
the component in mixtures, on mixing of excipients with the
drug.der isothermal stress testing after 4 weeks of storage.
maininga Change in physical appearance
mple Stressedc sample
.2 99.97 ± 3.1 No
.7 99.56 ± 3.0 No
.1 102.34 ± 0.7 No
.2 101.87 ± 1.1 No
.5 100.12 ± 2.2 No
.1 100.02 ± 1.1 No
r.
r 4 weeks.
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Pure lamivudine showed the characteristic band peaks at
1651.12 cm1 which corresponds to cystedine nucleus. Charac-
teristic bands that peak at 3407.58 cm1 and 3198.77 cm1 rep-
resent the amino and hydroxy groups present in lamivudine.
Peaks present at 1287.37 cm1 and 1160.32 cm1 represent
the asymmetrical and symmetrical stretching of C–O–C group
present in the oxathiolane ring of lamivudine. All the binary
mixtures of drug and excipient showed no type of physical
interaction except with magnesium stearate. In FT-IR spectral
diagram of drug-magnesium stearate there is introduction of
absorption bands at 2955.18 cm1 and 2850.32 cm1, which
might be a type of physical interaction, but in thermal analysis
(DSC and isothermal stress testing) there was no conﬁrmation
for the same.
3.3.3. Isothermal stress testing study
In the isothermal stress testing, drug–excipient binary mixtures
showed no change in physical appearance at ambient temper-
ature. The blends remain physically stable and no discolor-
ation, liquefaction or gas formation was observed during
storage. There was no signiﬁcant drug degradation, observed
in all drug-excipients mixture. Table 3 showed percent of drug
remaining at the end of the study at 50 C.3.4. Formulation development
The Lamivudine (LAM) controlled release tablets were formu-
lated using direct compression techniques. Spray dried lactose
was selected as direct compression diluents by considering its
advantages in terms of good compressibility, easy availability,
cost effectiveness and low moisture sensitivity. PVP K-30 was
used as dry binder considering its widespread applicability in
industry and relatively low moisture sensitivity. Magnesium
stearate and talc were used as lubricant and glidant respec-
tively due to their widespread applicability in industry and rel-
atively low moisture sensitivity. Highly substituted acetylated
sago starch (ASS) was used as hydrophobic polymeric carrier
material for the production of oral controlled release tablet
The batches of tablets from F1 to F8 were prepared to select
the suitable concentrations of ASS. The tablets were formu-
lated to attain 8 kg/cm2 hardness with varying concentration
of ASS (25–200 mg/tablet). The tablets were formulated with-
out any processing difﬁculties (stickiness, lamination, capping
and picking).Table 4 Physical properties of lamivudine matrix table using acety
Batches Drug content (%) Weight deviation (mg)
F1 102.2 ± 1.1 406 ± 2.4
F2 100.98 ± 2.1 401 ± 1.3
F3 101.56 ± 1.2 407 ± 0.6
F4 103.12 ± 1.9 409 ± 2.7
F5 102.6 ± 1.2 404 ± 2.4
F6 101.98 ± 2.4 399 ± 2.1
F7 102.1 ± 0.6 404 ± 1.8
F8 103.2 ± 2.5 406 ± 2.5
All values represent mean ± standard deviation; (n= 3).3.5. Evaluation of physical parameters of tablets
3.5.1. General appearance and thickness
The tablets of all the batches were white in color, ﬂat, round
shaped and plane from both sides. The tablet thickness
(4.56 ± 0.5 mm to 4.65 ± 2.2 mm) and physical properties
of all the batches of tablets are shown in Table 4.
3.5.2. Weight variation
The average weight of 20 tablets along with standard deviation
of entire formulations has been presented in Table 4. The per-
centage of weight variation of individual tablets from the aver-
age weight was found to be within ±5% w/w which proved
that all the tablets have passed the USP weight variation test.
3.5.3. Drug content
The drug content of all the tablets in each batch was found to
be in the range of (100.98 ± 2.1% to 103.21 ± 1.9%) and is
shown in Table 4. The results indicated that tablets of entire
batches have passed the USP criteria for the drug content of
tablets.
3.5.4. Hardness
The hardness of tablets of entire batches was found to be in the
range of 8.00 ± 1.4 kg/cm2 to 8.3 ± 2.1 kg/cm2 and the results
are depicted in Table 4.
3.5.5. Friability
The results of the friability test of entire formulations are de-
picted in Table 4. It was observed that the tablets of entire
batches had passed USP criteria of friability testing
(<1.00%w/w). The results revealed that tablets possess good
mechanical strength.
3.6. In vitro drug release study of all batches
The results of in vitro drug release study (n= 6) of all the
batches of tablets is shown in Fig. 1. From the drug release
proﬁle of the batches from F1 to F4 it is seen that the total
amount of drug was released within 6 h, while from the batches
F5 and F6, the total amount of drug was released within 8 h.
Release proﬁle of batch F7 showed a superior ﬁt to the desired
control drug release proﬁle among all the batches. The tablets
of batch F8 (with highest concentration of ASS) also showed a
controlled release pattern but signiﬁcantly less amount of druglated sago starch (ASS) as release retardant.
Hardness (kg/cm2) Friability (%) Thickness (mm)
8.0 ± 1.4 0.53 ± 2.3 4.56 ± 0.5
8.1 ± 1.7 0.44 ± 0.7 4.65 ± 2.2
8.2 ± 2.1 0.43 ± 2.1 4.63 ± 2.4
8.2 ± 2.0 0.41 ± 1.7 4.64 ± 1.1
8.2 ± 1.3 0.38 ± 2.5 4.61 ± 1.2
8.2 ± 1.1 0.39 ± 1.4 4.63 ± 2.1
8.31 ± 2.1 0.24 ± 2.2 4.64 ± 2.8
8.2 ± 1.9 0.22 ± 0.21 4.62 ± 2.4
Figure 1 Comparative in vitro dissolution proﬁle of all batches (mean value ± SD).
198 A.V. Singh, L.K. Nathwas released from them, so batch F8 was not considered for
further study.
The result of drug release proﬁle of the batch F7 showed the
release of 28% w/w of drug during initial 2 h, while within the
ﬁrst 6 h 68% of drug was released and the remaining 32% w/w
of the drug was released during the remaining 6 h. Hence, a
controlled release pattern of drug was observed from the tab-
lets of batch F7 throughout the 12 h of dissolution study.
3.7. Kinetics and mechanism of drug release
The release rate constant was calculated from the slope of the
appropriate equations and the correlation coefﬁcient (R) was
determined for all formulations (Table 5). The in vitro drug re-
lease of optimized batch (F7) was best ﬁtted and explained by
Higuchi Kinetics with highest linearity (RH = 0.9781), fol-
lowed by zero order (RO = 0.9617) and ﬁnally ﬁrst order
(RF = 0.896) kinetics. This explains that F7 found to be best
ﬁtted in Higuchi kinetics as compared to other kinetics study.
All other batches showed neither high correlation value (R)
nor acceptable K value (low). This explains that the drug re-
lease from controlled release tablet prepared with ASS withTable 5 Comparative release kinetics parameter of all the batches
Formulation Code Release kinetic parameters
Zero order First order
RO KO RF KF
F1 0.8347 24.7 0.9238 0.57
F2 0.887 19.65 0.9632 0.42
F3 0.9231 14.15 0.9639 0.35
F4 0.9231 14.15 0.9463 0.29
F5 0.9163 13.55 0.9561 0.25
F6 0.9259 9.90 0.9087 0.20
F7 0.9617 8.23 0.896 0.15
F8 0.9517 6.37 0.9994 0.05highest DS value followed primarily diffusion controlled
mechanisms. The model drug LAM was assumed to be dif-
fused only through the pores that were formed by dissolution
of dispersed drug particles i.e. the drug release mechanism was
leaching of dissolved drugs through the pores. Inter-particulate
porosity is essential for solvent penetration into the monolithic
matrix and consequently for drug release. The drug release
mechanism from controlled release devices is very complex
to explain and still not yet completely understood. Although
some controlled release processes may be classiﬁed as either
purely diffusional or purely erosion controlled and many oth-
ers can only be interpreted as being governed by both the
mechanisms. To evaluate the in vitro drug release proﬁle, the
data at various time points were ﬁtted into the Korsemayer–
Peppas equation. In this equation Kp is the release rate con-
stant and np is the characteristics for the mechanism of drug
release. With an np value of 0.5, the equation becomes equal
to the square root model described by Higuchi, which signiﬁes
that drug release from the matrix is governed by Fickian diffu-
sion, for np value 0.5–1.0, anomalous non-ﬁckian drug diffu-
sion occurs i.e. combination of both diffusion or swelling as
well as erosion mechanism. For np > 1, non-ﬁckian case-II,of controlled release tablets.
Higuchi Korsemeyer and Peppas
RH KH Rp np
4 0.9616 53.61 0.8773 0.515
53 0.9809 47.67 0.9597 0.574
8 0.9655 44.58 0.9549 0.676
53 0.9796 41.06 0.9813 0.659
56 0.9695 39.35 0.9723 0.711
17 0.9751 35.51 0.9819 0.705
34 0.9781 32.09 0.9948 0.734
65 0.9836 25.03 0.9843 0.743
Table 6 Pharmacokinetic parameters of marketed and optimized controlled release tablet (F7) after a single oral dose of 100 mg
lamivudine to rabbits (n= 3).
Pharmacokinetic parameters Observed value (Lamivir) Observed value (F7)
Maximum plasma concentration, Cmax (ng/mL) 12784.913 ± 2.1 9575.611 ± 3.1
Time required to reach maximum plasma concentration, Tmax (h) 1.00 ± 1.6 4.00 ± 2.8
Area under curve at 24 h, AUC (0ﬁ1) (ng h/mL) 54206.284 ± 3.7 66000.541 ± 1.9
Area under momentum curve At 24 h, AUMC (0ﬁ1) (ng h
2/mL) 227067.968 ± 0.6 340619.953 ± 1.4
Volume of distribution, Vd (L) 9.574 ± 2.8 19.970 ± 1.3
Plasma half life (T1/2) (h) 3.594 ± 0.2 9.080 ± 2.1
Absorption rate constant, Ka (h1) 2.142 ± 1.8 0.834 ± 1.7
Elimination rate constant, Ke (h1) 0.193 ± 1.5 0.083 ± 1.9
Mean residence time, MRT (h) 4.189 ± 2.1 5.161 ± 1.2
Clearance, Cl (L/h) 1.846 ± 3.0 1.529 ± 1.8
Figure 2 Comparative in vivo pharmacokinetic study of mar-
keted conventional and optimized formulation (F7).
Evaluation of chemically modiﬁed hydrophobic sago starch 199erosion controlled or zero order release kinetics is followed.
The Rp and np values of various batches of tablets are depicted
in Table 4. The Rp values of 0.8773, 0.9597, 0.9549, 0.9813,
0.9723, 0.9819, 0.9948 and 0.9843 for the batches of tablets
F1, F2, F3, F4, F5, F6, F7 and F8 respectively which showed
good linearity between log cumulative amount of drug release
versus log time, and the highest linearity was observed with F7,
where the concentration of ASS as release retardant polymer is
quite high. The np values were found to be 0.515, 0.574, 0.676,
0.659, 0.711, 0.705, 0.734 and 0.743 for the tablets F1, F2, F3,
F4, F5, F6, F7 and F8 respectively. Hence, the mechanism of
drug release from the tablets was predicted from Korsemayer–
Peppas equations and from the obtained np values of all the
batches of tablets (np > 0.5) it is revealed that the mechanism
of drug release was a coupling of both the process of diffusion
and erosion.
3.8. In vivo pharmacokinetics
The results of the plasma drug concentration at different time
intervals, after administration of controlled release tablets con-
taining 100 mg of lamivudine to three rabbits, are presented in
Table 6. The drug remained in the body of the animals up to
24 h of administration of the tablet. The comparison of the
different parameters was done by using a one-way analysis of
variance (ANOVA). A value of p< 0.05 was considered statis-
tically signiﬁcant. The pharmacokinetic parameters were
derived from plasma drug concentrations versus time proﬁle
of all the subjects and the results are shown in Table 6. TheTmax
of controlled release tablets was found to be 4 h, as compared to
1 h for the marketed conventional tablet (Lamivir), which
indicates the slow absorption rate from the controlled release
tablets due to extended release effect of hydrophobic polymer
present in controlled release tablets. The average Cmax value
of the controlled release tablet (12784.91 ± 2.1 ng/mL) was de-
creased as compared to conventional tablet (9575.611 ± 3.1
ng/mL). The AUC0–1 of controlled release tablets of lamivu-
dine exhibited high value (66000.54 ± 1.9 ng h/mL)) as com-
pared to conventional tablets (54206.284 ± 3.7 ng h/mL). The
AUMC0–1 was found to be 340619.953 ± 1.4 ng h/mL (high)
as compared to 227067.96 ± 0.6 ng h/mL (low) to the conven-
tional tablets. The mean Vd and clearance values for controlled
release tablets were found to be 19.97 ± 1.3 L and 1.529 ±
1.8 L/h respectively. The Ka and Ke value for controlled release
tablets was found to 0.834 ± 1.7 h1 and 0.083 ± 1.9 h1respectively which are lower than the values of conventional
tablets. The mean residence time (MRT) of controlled release
tablets was found to be higher (5.161 ± 1.2 h) than that of con-
ventional tablets (4.189 ± 2.1 h) conﬁrming the controlled re-
lease property of the modiﬁed starch ASS. The results
revealed that the drug was made available to the body in a con-
trolled release manner and the controlled release effect was due
to the presence of higher proportion of ASS in the tablet as evi-
dent from the Fig. 2.
3.9. Stability study
The selected optimized formulation (F7) was evaluated for
various parameters (drug content, dissolution study) after 3
and 6 months of storage at accelerated stability conditions
(40 ± 2 C and 75%± 5% RH). There was no signiﬁcant
amount of change observed in the drug content of tablets after
6 months of storage at accelerated stability conditions. The
dissolution proﬁle of formulation at the initial stage was con-
sidered as the reference for dissolution study. The results ob-
tained revealed that the dissolution proﬁle of the formulation
after 6 months of storage at accelerated conditions was found
to be similar to that of the reference one. Based on the results it
was opined that the tablets of batch F7 were stable after
6 months of storage at accelerated stability conditions.
200 A.V. Singh, L.K. Nath4. Conclusion
The present study focused on the formulation of 12 h con-
trolled release tablets of lamivudine using ASS as matrix form-
ing hydrophobic polymer. It was summarized from the
dissolution studies that the tablets containing less concentra-
tion of ASS were disintegrated within 1.0 h and the release
of drug was not controlled. At higher concentration of ASS
the tablets released the drug in a controlled manner over
12 h study. The study of release mechanism exhibited anoma-
lous non-ﬁckian diffusion that involved both diffusion and
erosion mechanisms. The pharmacokinetic study of the opti-
mized batch (F7) in rabbits was carried out in triplicate. The
plasma drug concentration versus time interval was estimated
by using in house developed RP-HPLC method procedure.
The optimized controlled release tablets exhibited ﬁrst order
absorption rate kinetics in the release of drug from the tablets.
The increase in Tmax value and decrease in Cmax value in case
of the optimized formulation F7 from the values of the con-
ventional tablet of lamivudine (Lamivir) revealed that the
acetylated sago starch (ASS) in the controlled release tablets
rendered the drug to be released in a controlled manner.
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